

Timely adjuvant chemotherapy improves outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy

Running Title: Timing of chemotherapy for splenic HSA

Eugenio Faroni¹, Silvia Sabattini¹, Dina Guerra¹, Chiara Iannuzzi¹, Carmit Chalfon¹, Chiara Agnoli¹, Damiano Stefanello², Gerry Polton³, Sofia Ramos³, Marina Aralla⁴, Raffaele Ciacchini⁵, Armando Foglia¹, Samuel Okonji¹, Laura Marconato¹

¹ Department of Veterinary Medical Sciences, Alma Mater Studiorum University of Bologna, Ozzano dell'Emilia (BO), Italy

² Department of Veterinary Medicine and Animal Sciences, University of Milan, Lodi (LO), Italy

³ North Downs Specialist Referrals, Bletchingley, United Kingdom

⁴ Pronto Soccorso Veterinario Laudense, Lodi (LO), Italy

⁵ Clinica Veterinaria Ponte Felcino, Perugia (PG), Italy

Corresponding author:

Eugenio Faroni

Department of Veterinary Medical Sciences, *Alma Mater Studiorum* University of Bologna

Via Tolara di Sopra, 50

40064 Ozzano dell'Emilia (BO), Italy

eugenio.faroni@unibo.it

Acknowledgements

None.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1111/vco.12875](https://doi.org/10.1111/vco.12875)

Ethical Statement

Authors declare that approval by an ethics committee was not required.

Timely adjuvant chemotherapy improves outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy

Word count: 3167

Number of figures and tables: 2 figures, 4 tables

Conflict of interest declaration: The authors declare that there is no conflict of interest.

Abstract

Timely delivery of adjuvant chemotherapy has been shown to be advantageous in many human cancers and canine osteosarcoma. Adjuvant chemotherapy has been shown to improve outcome for canine splenic hemangiosarcoma. The aim of this retrospective study was to investigate whether timely adjuvant chemotherapy administration resulted in better outcome in dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy. Medical records were searched for dogs with non-metastatic, splenic hemangiosarcoma that received splenectomy and adjuvant chemotherapy. The number of days from surgery to the first chemotherapy dose (StoC) was evaluated to identify the cut-off value associated with the best survival advantage. StoC and other possible prognostic factors were tested for influence on time to metastasis (TTM) and overall survival (OS). Seventy dogs were included. Median StoC was 20 days (range, 4-70). The time interval associated with the greatest survival benefit was 21 days. Median TTM and OS of dogs with StoC ≤ 21 days were significantly longer than those with StoC > 21 days (TTM: 163 vs. 118 days, $P=0.001$; OS: 238 vs. 146 days, $P<0.001$). On multivariable analysis, StoC > 21 days was the only variable significantly associated with increased risk of tumor progression (HR 2.1, $P=0.010$).

and death (HR 2.3; P=0.008). Starting adjuvant chemotherapy within 21 days of surgery may be associated with a survival benefit in dogs with non-metastatic splenic hemangiosarcoma, possibly due to the early targeting of newly-recruited metastatic cells after surgery.

Keywords

Canine, doxorubicin, micrometastasis, prognosis, spleen, surgery

Introduction

In dogs, hemangiosarcoma (HSA) is a common and aggressive cancer of vascular origin. The spleen is the most common primary site, with nearly 50% of dogs having evidence of metastatic disease at presentation.^{1,2} Splenectomy as the sole treatment modality is considered palliative; the addition of adjuvant doxorubicin-based chemotherapy usually only increases the average survival time by 2–4 months.³⁻⁵

There is accumulating evidence that surgical resection may enhance metastatic shedding of tumor cells. According to several hypotheses, surgery may promote tumor cell migration or trigger the outgrowth of resting metastatic cells through the release of inflammatory factors, catecholamines and pro-metastatic enzymes.^{6,7} In addition, surgery-induced local and systemic immunosuppression can impair antitumor immunity (e.g., decreased number of natural killers [NK] and monocyte/macrophages, release of inflammatory cytokines such as TNF- α and IL-1), contributing to tumor cell survival.⁸⁻¹¹ While timely delivery of adjuvant chemotherapy may prevent these undesired effects, early administration may result in increased toxicity rates.¹² Additionally, although never reported in dogs, there is a concern that early chemotherapy administration may increase post-surgical complications, including delayed wound healing and enhanced immunosuppression, due to cytotoxic effects on fibroblasts, thrombocytes, monocytes and leucocytes, inhibition of keratinocytes proliferation and decreased collagen synthesis.¹³⁻¹⁸

The timing of administration of adjuvant chemotherapy is a well-known prognostic variable for many human cancers (e.g., osteosarcoma, colon cancer), and it has gained growing interest in the veterinary community as well, with studies in mice and dogs reporting its impact.¹⁹⁻²² Recently, Marconato et al. demonstrated a survival benefit in dogs with appendicular osteosarcoma that received chemotherapy within 5 days of limb amputation.²³

Variations in intervals between surgery and chemotherapy are common in clinical practice. This may depend on patients' medical conditions, owner's compliance and on the availability of a definitive diagnosis.

The aim of this study was to determine whether different time intervals between surgery and the first administration of chemotherapy would result in different outcomes, possibly identifying an optimal prognostic cut-off. Given the highly aggressive behaviour of canine splenic HSA, we hypothesized that starting chemotherapy early after splenectomy would improve outcome by targeting newly-recruited cycling metastatic cells after surgery.

Materials and Methods

Study Design

This was a retrospective study on client-owned dogs with spontaneous tumors seeking medical advice at a clinical facility. As the research did not influence any diagnostic or therapeutic decision, approval by an ethics committee was not required. All the examined samples and data were collected for diagnostic purposes as part of routine standard care.

The archives of seven veterinary oncology centers were retrospectively searched for dogs with splenic HSA undergoing splenectomy between January 2004 and December 2021. Dogs were included if they had a histologically confirmed splenic HSA, no evidence of metastases at the start of chemotherapy and received at least 1 dose of adjuvant cytotoxic chemotherapy. Dogs with

incomplete staging or follow-up data were excluded. All owners provided written informed consent to the use of their dogs' medical records.

Collected information included signalment (i.e., breed, sex, neutering status, age, weight), presence and duration of clinical signs, clinical stage according to the World Health Organization staging system of domestic animals,²⁴ results of hematologic and coagulation analyses (i.e., complete blood count [CBC], serum biochemical profile, coagulation profile [i.e., activated partial thromboplastin time, prothrombin time], urinalysis), and need for blood product administration.

Pre-chemotherapy staging was required to be performed by means of total body CT scan (TBCT) or 3-view thoracic radiographs, abdominal ultrasound, and echocardiography, in addition to cytological or histologic evaluation of any suspicious visceral lesion.

All dogs received adjuvant chemotherapy, consisting of single agent doxorubicin (intravenous, q3 weeks), or a combination of doxorubicin and dacarbazine, as previously described.²⁵ For each case, the number of days between surgery and the first administration of chemotherapy (*surgery to chemotherapy*, StoC) was retrieved.

Routine monitoring for pulmonary and abdominal metastasis with thoracic radiographs and abdominal ultrasound, respectively, occurred every 2-3 cycles of chemotherapy, unless clinical signs suspicious for metastasis were present, in which case imaging was carried out sooner. Once chemotherapy was completed, dogs were restaged every 2-3 months.

In case of disease progression, metronomic therapy was offered. Also, based on owners' and clinicians' preference, dogs could receive metronomic therapy at the end of the doxorubicin-based protocol.

Clinical, hematologic, and biochemical chemotherapy-related adverse events (AEs) were assessed based on patient history provided by the owner, physical examination and blood work. AEs were

graded according to the Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events (VCOG-CTCAE) v2 and retrieved from medical records.²⁶

Statistical Analysis

Categorical variables were summarized as frequency (percentage), while numerical variables were summarized as median (range). Non-normality of numerical data was assessed using the Shapiro–Wilk test.

Time to metastasis (TTM) was defined as the time interval between the first administration of chemotherapy and detection of metastasis. Metastasis was defined as the clinical and/or imaging evidence of suspected tumoral lesion(s) in any anatomic site, with cytologic confirmation (when possible) and/or progression of lesion(s) during follow-up. Overall survival (OS) was defined as the time interval between surgery and death due to any cause. Survival estimates were computed as medians and 95% CIs.

Cox proportional hazards regression was performed to evaluate the influence of potentially prognostic variables on TTM and OS, including sex, neutering status, age, body weight, presence of clinical signs prior to diagnosis, type of imaging used for tumor staging (TBCT vs other), hemoabdomen, anemia (hematocrit < 37%), thrombocytopenia (total platelet number < 160000/ μ L), coagulation abnormalities, blood product administration, chemotherapeutic protocol (doxorubicin vs doxorubicin and dacarbazine), administration of metronomic chemotherapy, and chemotherapy-related AEs. The continuous variables of age and body weight were converted to dichotomous variables with the median value used as the cut-off point. Variables with a P value < 0.2 in the univariable analyses were further tested for independence of association with outcome in a multivariable Cox proportional hazards model.

StoC was analyzed as a categorical variable (within 7, 14, 21, 28, or > 28 days after surgery). The risk of tumor metastasis and death of the dogs within each interval category for StoC was then compared with that of the remaining dogs (e.g., ≤ 7 days vs > 7 days, and ≤ 14 days vs > 14 days) by means of Cox proportional hazards regression, and the interval with the highest, significant ($P < 0.05$) HR was selected as the optimal interval and included in the multivariable model.

The two groups identified by the optimal interval were tested for distribution of the aforementioned possible prognostic variables and time of restaging by means of chi-square/Fisher's exact test and Mann-Whitney U test for categorical and continuous variables, respectively. Survival curves were generated with the Kaplan-Meier product limit method and then compared between StoC groups with the log-rank test. One-year survival rates of different StoC-defined groups were obtained.

Cell Line Validation Statement

No cell lines were used in the current study.

Results

Patients' characteristics

Seventy dogs were included in the study. There were 37 (53%) males, of which 14 were neutered, and 33 (47%) females, of which 26 were spayed. Median age was 10 years (range, 6–15), and median weight was 28 kg (range, 6–58). The most represented breeds were mixed ($n=21$; 30%), Labrador retriever ($n=11$; 16%), and German shepherd ($n=5$; 7%).

Sixty-three (90%) dogs were symptomatic at admission, with median duration of clinical signs of 2 days (range, 1 – 46), while HSA was an incidental finding in 7 (10%) cases. Reported clinical signs were lethargy, reduced appetite, exercise intolerance, tachypnea, and syncope.

Results of CBC were available for 64 (91%) cases. Forty nine (77%) dogs were anemic, with a median hematocrit of 29% (range, 13-36). Twenty-eight (44%) dogs were thrombocytopenic, with a median platelet number of 89000/ μ L (range, 16000-153000). Results of coagulation times were available for 51 (73%) cases, with abnormal results registered in 4 (8%) of those.

Tumors were staged by means of 3-view thoracic radiography and abdominal ultrasonography in 49 (70%) dogs, whereas 21 (30%) underwent TBCT scan. At admission, hemoabdomen was present in 58 (83%) dogs. Overall, 59 (84%) and 11 (16%) dogs had stage 2 and stage 1 disease, respectively.

Treatment

Following splenectomy, no complication in wound healing was reported.

Eight (11%) dogs received heterologous packed red blood cells during the surgical procedure.

All dogs received adjuvant chemotherapy: 66 (94%) dogs received doxorubicin as single agent (median, 4 doses; range, 1 to 6 doses), while 4 (6%) received doxorubicin and dacarbazine (median, 4 doses; range, 2 to 6 doses). The median doxorubicin dose was 30 mg/m² (range, 25 to 50 mg/m²), and the median dacarbazine dose was 200 mg/m² (range, 160 to 210 mg/m²).

Chemotherapy-related AEs were experienced by thirty (43%) dogs, of which nine (13%) had grade 3 or 4 toxicity. Overall, there were twenty-four episodes of gastrointestinal toxic effects, including four grade 3 (n=2 vomiting, n=1 diarrhea) and one grade 4 (diarrhea); there were four episodes of hematologic toxicity, including three grade 4 (neutropenia in all cases). The three dogs with grade 4 hematologic toxicity required 1-week dose delay. The dog with grade 4 gastrointestinal toxicity and one dog with grade 3 gastrointestinal toxicity (vomiting) had their chemotherapy protocol stopped after a single dose of doxorubicin at the owners' request.

Overall, 36 (51%) dogs completed the planned course of cytotoxic chemotherapy. Twenty (29%) dogs received metronomic chemotherapy as a rescue treatment at the detection of metastasis, and 21 (30%) as maintenance therapy after completion of the cytotoxic chemotherapy protocol. Twenty-six dogs received thalidomide, cyclophosphamide and piroxicam; 11 dogs received cyclophosphamide and firocoxib; 4 dogs received cyclophosphamide as single drug. Median thalidomide, cyclophosphamide, piroxicam and firocoxib doses were 4 mg/kg (range, 3.5-8), 10 mg/m² (range, 7-13), 0.3 mg/kg (range, 0.1-0.4) and 5 mg/kg (range, 4-5), respectively.

Outcome

At data analysis closure, 63 (90%) dogs were dead, while 7 (10%) were still alive after a median follow-up time of 212 days (range, 102-1274). Among dead dogs, 60 (95%) and 3 (5%) dogs were dead for tumor-related and tumor-unrelated (2 gastric-dilatation-volvulus, 1 cardiac failure due to an end-stage myxomatous mitral valve disease) causes, respectively. One-year survival rate was 9%. Median TTM was 142 days (95% CI, 103-181) and median OS was 165 days (95% C, 141-189). Median StoC was 20 days (range, 4-70). Specifically, StoC was ≤ 7 , ≤ 14 , ≤ 21 , and ≤ 28 days in 4, 22, 39 and 57 dogs, respectively. The only cut-off significantly associated with a survival benefit was StoC ≤ 21 days. The median TTM of dogs with StoC ≤ 21 days (163 days, 95% CI 103-223) was significantly ($P=0.001$) longer than that of those with StoC >21 days (118 days, 95% CI 96-140; Figure 1). The median OS of dogs with StoC ≤ 21 days (238 days, 95% CI 184-292) was significantly ($P<0.001$) longer than that of those with StoC >21 days (146 days, 95% CI 129-163; Figure 2). One-year survival rate of dogs with StoC ≤ 21 days and that of those with StoC >21 days were 16% and 0%, respectively.

On univariable analysis (Table 1), StoC >21 days was the only variable significantly associated with an increased risk of tumor metastasis (HR 2.5, 95% CI 1.4-4.2, $P=0.001$). When adjusting for other

variables with $P < 0.2$ (i.e., intact status; Table 2), Stoc > 21 days remained the only significant variable (HR 2.3, 95% CI 1.3-4.0, $P = 0.003$). On univariable analysis for risk of death (Table 1), intact status (HR 1.8, 95% CI 1.1-3.1, $P = 0.02$) and Stoc > 21 days (HR 2.8, 95% CI 1.6-5.1, $P < 0.001$) were both significant. When adjusting for all variables with $P < 0.2$ (i.e., intact status, staging without TBCT, lack of maintenance metronomic chemotherapy; Table 3), Stoc > 21 days remained the only variable independently associated with an increased risk of death (HR 2.5, 95% CI 1.4-4.6, $P = 0.002$).

Analysis of distribution of possible prognostic variables between dogs with Stoc ≤ 21 days and dogs with Stoc > 21 days is reported in Table 4. Dogs with Stoc > 21 days were more frequently of intact status than dogs with Stoc ≤ 21 days ($P = 0.029$). None of the remaining evaluated variable was differently distributed.

Discussion

Considering the highly aggressive behavior of splenic HSA and the limited overall benefit of medical therapy, our hypothesis was that timely administration of adjuvant chemotherapy would positively influence patients' outcome. Based on our findings, Stoc ≤ 21 days resulted in a significantly longer median TTM (163 vs 118 days), and overall survival (238 vs 146 days) compared to dogs receiving their first dose of adjuvant chemotherapy > 21 days from surgery. Notably, 1-year survival rate of dogs with Stoc ≤ 21 days (i.e., 16%) was higher than that of dogs with Stoc > 21 days (i.e., 0%).

These findings are in line with pre-clinical and clinical studies, both in human and veterinary medicine.¹⁹⁻²³ The aim of administering adjuvant cytotoxic chemotherapy for splenic HSA is to target and kill rapidly-cycling neoplastic cells. There are many reasons to believe that early administration of adjuvant chemotherapy would result in a benefit for the patient. In 2006,

Harless and Qiu proposed a mathematical model indicating that increasing tumor burden would result in decreased chemotherapy efficacy, and that the longer the time interval between tumor removal and chemotherapy delivery, the greater the tumor burden.²⁷ It is well documented that quiescent micrometastases may re-enter the cell cycle after surgery and, with time, macrometastases may become clinically evident.²⁸⁻²⁹ In fact, the removal of the primary tumor is associated with the release of many growth factors (e.g., catecholamines, prostaglandins), which stimulate angiogenesis and potentially trigger the outgrowth of latent distant disease; surgery-induced immunosuppression, caused by reduction in NK cell number and cytotoxic activity, impairment of monocytes/macrophages phagocytic and chemotactic function, or release of inflammatory cytokines (e.g., TNF- α and IL-1) into circulation, may further favor this process.^{6,7,9-11} Additionally, a long interval between surgery and chemotherapy administration may lead to the development of a chemo-resistant phenotype due to the accumulation of spontaneous mutations in replicating tumor cells.³⁰

In the present study, median StoC was 20 days; this is in line with a recent study by Finotello et al.,³¹ whereas two studies reported shorter times.^{1,25} This relatively long interval may be due to several reasons. In most cases, surgery for splenic HSA is an emergency procedure, as most dogs present with hemoabdomen due to mass rupture. Clinical conditions may require hospitalization in intensive care unit after surgery, thereby postponing discharge, together with the administration of the first dose of adjuvant chemotherapy. In addition, the ability to obtain a pre-operative diagnosis of HSA is limited, due to the poor sensitivity of cytology in identifying vascular neoplasms;³²⁻³⁴ thus, the final histopathologic report is critical to guide possible adjuvant treatment decisions. Moreover, the spleen, being a blood-rich organ, generally requires longer formalin fixation times (e.g., up to 48-72 hours), increasing histologic processing and reporting time. The time interval of 21 days, which was significantly associated with the outcome in this

study, is generally adequate for a patient to fully recover from surgery and for the final histopathologic report to be delivered.

Chemotherapy-related AEs did not increase with shorter StoC (i.e., 7, 14 days) and it is possible that shorter StoC intervals would have resulted in a survival benefit with a larger sample size available. On the other hand, one must question whether excessively early chemotherapy delivery can be counterproductive. An unacceptable level of toxicity has been reported in dogs with osteosarcoma receiving cisplatin and doxorubicin two days after surgery.¹² In addition, many anesthetic drugs (e.g., opioids, inhalant anesthetics) and surgery itself are known to cause transient immunosuppression.³⁵⁻³⁹ A further immunosuppressive effect induced by chemotherapeutic drugs may put the dog at risk of major complications (e.g., sepsis). Furthermore, the cytotoxic effect and impaired collagen biosynthesis consequent to anthracycline and alkylating agents' administration could antagonize surgical wound repair.^{13,15} In that scenario, waiting for the patient to recover after surgery may eventually translate in an improved outcome. Here, however, no adverse effect on wound healing was registered, even in dogs receiving adjuvant chemotherapy within 7 or 14 days from surgery.

StoC >21 days was the only variable independently associated with an increased risk of both tumor metastasis and death. Other factors influencing outcome in previous studies (e.g., hemoabdomen, thrombocytopenia, administration of blood products)^{2,40} failed to demonstrate a prognostic role in the current population. Unfortunately, groups defined by some variables were not numerically homogenous. Notably, hemoabdomen was present in 83% of dogs, and we cannot exclude that this or other variables would have emerged as prognostic factors with similar number of cases in each group.

In disagreement with a previous study,²⁵ the chemotherapy protocol did not influence outcome in this cohort. However, only 4 dogs received doxorubicin and dacarbazine as a multidrug protocol,

thus it is possible that this low number of patients may have prevented a real significance to be revealed. Again, in disagreement with the published literature,³¹ no apparent benefit of metronomic chemotherapy was observed. However, only 21 dogs received metronomic chemotherapy after completion of the cytotoxic protocol, while almost the same number received it as a rescue treatment.

Interestingly, HSA was an incidental finding in more than 10% of cases. This is uncommon, as splenic HSA is almost always symptomatic for active or previous hemoperitoneum due to mass rupture. It is possible that these cases, which often translate into stage I HSA, had a better outcome, but were well-distributed among the two groups, thereby minimizing a possible influence on the analysis.

This study has several limitations, mainly due to its retrospective nature. The population size was small and not homogeneous in terms of treatment; additionally, dogs receiving dacarbazine were underrepresented. An increased sample size would have possibly allowed for more significant findings to emerge, both in terms of StoC and other prognostic variables. There was a limited number of cases receiving chemotherapy within 7 and 14 days, but this represents daily clinical practice, as many variables (e.g., peri-operative complications, waiting for histopathology report, owners' decision-making, ordering and scheduling of treatment) may play a role in the timing of the first administration of chemotherapy. Furthermore, follow-up was not standardized, potentially affecting calculation of TTM.

Overall, the population was homogenous regarding common prognostic variables. Without TBCT, smaller metastases may not be revealed, increasing the risk of underestimating tumor stage, and including dogs with distant metastasis. It must be noted, however, that 70% of dogs in this cohort did not undergo TBCT, and StoC-based groups were uniform regarding this variable, too, minimizing a possible influence on inclusion and outcome.

Unfortunately, histologic slides were not available for re-evaluation, thus preventing inclusion of histologic variables in the analysis of prognostic factors. Mitotic count was recently associated with outcome by Moore et al.,⁴¹ and may have possibly influenced prognosis in this cohort, too.

In conclusion, the advantages of timely administration of adjuvant chemotherapy in dogs with non-metastatic splenic HSA are supported by the current findings, being associated with longer TTM and survival. Based on this study, the authors recommend that oncologists and their teams collaborate to find strategies to shorten recovery time and interval from presentation to diagnosis to reduce the likelihood of the surgery to chemotherapy interval for these patients becoming significantly prolonged.

In light of our preliminary results, prospective studies on HSA and other tumor types are warranted to assess whether shorter time intervals between surgery and administration of adjuvant chemotherapy would further improve outcome.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. Ciepluch BJ, Wilson-Robles HM, Pashmakova MB, Budke CM, Ellison GW, Thieman Mankin KM. Long-term postoperative effects of administration of allogeneic blood products in 104 dogs with hemangiosarcoma. *Vet Surg* 2018;47(8):1039-1045.
2. Marconato L, Chalfon C, Finotello R, et al. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic

hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology. *Vet Comp Oncol* 2019;17(4):537-544.

3. Sorenmo KU, Jeglum KA, Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. *J Vet Intern Med* 1993;7(6):370-6.
4. Sorenmo KU, Baez JL, Clifford CA, et al. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. *J Vet Intern Med* 2004;18(2):209-13.
5. Kahn SA, Mullin CM, de Lorimier LP, et al. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study. *Can Vet J* 2013;54(3):237-42.
6. Tohme S, Simmons RL, Tsung A. Surgery for Cancer: A Trigger for Metastases. *Cancer Res* 2017;77(7):1548-1552.
7. Chen Z, Zhang P, Xu Y, et al. Surgical stress and cancer progression: the twisted tango. *Mol Cancer* 2019;18(1):132.
8. Sawai H, Funahashi H, Yamamoto M, et al. Interleukin-1alpha enhances integrin alpha(6)beta(1) expression and metastatic capability of human pancreatic cancer. *Oncology* 2003;65(2):167-73.
9. Yano S, Nokihara H, Yamamoto A, et al. Multifunctional interleukin-1beta promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules. *Cancer Sci* 2003;94(3):244-252.
10. Jing Y, Ma N, Fan T, et al. Tumor necrosis factor-alpha promotes tumor growth by inducing vascular endothelial growth factor. *Cancer Invest* 2011;29(7):485-493.
11. Alieva M, van Rheenen J, Broekman MLD. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. *Clin Exp Metastasis* 2018;35(4):319-331.
12. DeRegis CJ, Moore AS, Rand WM, Berg J. Cisplatin and doxorubicin toxicosis in dogs with osteosarcoma. *J Vet Intern Med* 2003;17(5):668-673

- Accepted Article
13. Robinson SJ, Nappi JF, Falcone RE. The effect of dacarbazine on wound healing. *J Dermatol Surg Oncol* 1988;14(9):975-8.
 14. Kolb BA, Buller RE, Connor JP, et al. Effects of early postoperative chemotherapy on wound healing. *Obstet Gynecol* 1992;79:988–92.
 15. Muszyńska A, Wolczyński S, Pałka J. The mechanism for anthracycline-induced inhibition of collagen biosynthesis. *Eur J Pharmacol* 2001;411(1-2):17-25.
 16. Payne WG, Naidu DK, Wheeler CK, et al. Wound healing in patients with cancer. *Eplasty* 2008;8:e9.
 17. Guo S, DiPietro LA. Factors affecting wound healing. *J Dent Res* 2010;89:219–29.
 18. Iodence AE, Wallace ML, Grimes JA, Schmiedt CW. Dogs undergoing surgical excision of mast cell tumors are not at increased risk of incisional complications. *J Am Vet Med Assoc* 2021;260(S1):S88-S95.
 19. Bell RS, Roth YF, Gebhardt MC, et al. Timing of chemotherapy and surgery in a murine osteosarcoma model. *Cancer Res* 1988;48(19):5533-8.
 20. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. *J Clin Oncol* 1992;10(1):5-15.
 21. Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. *Cancer* 2006;107(11):2581-2588.
 22. Imran H, Enders F, Krailo M, et al. Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. *J Bone Joint Surg Am* 2009;91(3):604-12.
 23. Marconato L, Buracco P, Polton GA, et al. Timing of adjuvant chemotherapy after limb amputation and effect on outcome in dogs with appendicular osteosarcoma without distant metastases. *J Am Vet Med Assoc* 2021;259(7):749-756.


24. Owen LN (Ed). *TNM Classification of Tumours in Domestic Animals*. Geneva, World Health Organization, 1980.
25. Finotello R, Stefanello D, Zini E, Marconato L. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma. *Vet Comp Oncol* 2017;15(1):25-35.
26. LeBlanc AK, Atherton M, Bentley RT, et al. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. *Vet Comp Oncol* 2021;19(2):311-352.
27. Harless W, Qiu Y. Cancer: A medical emergency. *Med Hypotheses* 2006;67(5):1054-9.
28. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. *Cancer Res* 1979;39(10):3861-5.
29. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. *Cancer Res* 1983;43(4):1488-92.
30. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. *Cancer Treat Rep* 1979;63(11-12):1727-33.
31. Finotello R, Henriques J, Sabattini S, et al. A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma. *Vet Comp Oncol* 2017;15(2):493-503.
32. Watson AT, Penninck D, Knoll JS, Keating JH, Sutherland-Smith J. Safety and correlation of test results of combined ultrasound-guided fine-needle aspiration and needle core biopsy of the canine spleen. *Vet Radiol Ultrasound* 2011;52(3):317-22.
33. Patten SG, Boston SE, Monteith GJ. Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001-2013). *Can Vet J* 2016;57(8):842-6.

- Accepted Article
34. Tecilla M, Gambini M, Forlani A, Caniatti M, Ghisleni G, Roccabianca P. Evaluation of cytological diagnostic accuracy for canine splenic neoplasms: An investigation in 78 cases using STARD guidelines. *PLoS One* 2019;14(11):e0224945.
 35. Yeager MP, Colacchio TA, Yu CT, et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. *Anesthesiology* 1995;83(3):500-508.
 36. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. *Anesth Analg* 2003;97(5):1331-1339.
 37. Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. *Neuroimmunomodulation* 2004;11(4):255-260.
 38. Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. *Nat Rev Clin Oncol* 2015;12(4):213-26.
 39. Longhini F, Bruni A, Garofalo E, et al. Anesthetic Strategies in Oncological Surgery: Not Only a Simple Sleep, but Also Impact on Immunosuppression and Cancer Recurrence. *Cancer Manag Res* 2020;12:931-940.
 40. Masyr AR, Rendahl AK, Winter AL, Borgatti A, Modiano JF. Retrospective evaluation of thrombocytopenia and tumor stage as prognostic indicators in dogs with splenic hemangiosarcoma. *J Am Vet Med Assoc* 2021;258(6):630-637.
 41. Moore AS, Rassnick KM, Frimberger AE. Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011-2014). *J Am Vet Med Assoc* 2017;251(5):559-565.


Figure legends

Figure 1. Time to metastasis for 70 dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy and adjuvant chemotherapy. In the group with a time interval between surgery and adjuvant chemotherapy (StoC) ≤ 21 days, dogs had a significantly longer time to metastasis than dogs with StoC > 21 days (median, 163 vs 118 days, respectively; $P=0.001$).

Figure 2. Overall survival for 70 dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy and adjuvant chemotherapy. In the group with a time interval between surgery and adjuvant chemotherapy (StoC) ≤ 21 days, dogs had a significantly longer overall survival than dogs with StoC > 21 days (median, 238 vs 146 days, respectively; $P<0.001$).



VCO_12875_Figure1rev.tif



VCO_12875_Figure2rev.tif

Table 1. Univariable Cox regression analysis of variables potentially associated with increased risk of tumor metastasis and death in 70 dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy and adjuvant chemotherapy.

Variable	Tumor metastasis		Death	
	Hazard Ratio (95% CI)	P	Hazard Ratio (95% CI)	P
Female sex	0.9 (0.6-1.5)	0.78	1.0 (0.6-1.6)	0.967
Intact status	1.6 (1.0-2.7)	0.059	1.8 (1.1-3.1)	0.02*
Age ≥10 years	1.1 (0.7-1.9)	0.656	1.1 (0.7-1.9)	0.647
Weight ≥28 kg	1.1 (0.7-1.9)	0.623	1.3 (0.8-2.1)	0.368
Presence of symptoms at admission	1.1 (0.5-2.5)	0.848	0.8 (0.4-1.9)	0.84
Staging without TBCT scan	1.3 (0.8-2.3)	0.345	1.6 (0.9-2.9)	0.115
Hemoabdomen	0.9 (0.5-1.7)	0.739	0.8 (0.4-1.4)	0.378
Anemia	1.4 (0.8-2.6)	0.287	1.0 (0.6-1.9)	0.914
Thrombocytopenia	1.1 (0.6-1.9)	0.727	1.1 (0.6-1.9)	0.748
Abnormal coagulation times	1.7 (0.6-4.7)	0.331	1.4 (0.5-3.9)	0.566
Blood products administration	0.9 (0.4-1.9)	0.723	0.8 (0.3-1.7)	0.507
StoC >21 days	2.5 (1.4-4.2)	0.001*	2.8 (1.6-5.1)	<0.001*
No metronomic therapy	NA	NA	1.5 (0.9-2.5)	0.138
Medical treatment toxicity	1.1 (0.6-2.0)	0.861	1.0 (0.5-1.9)	0.989

Abbreviations: CI, confidence interval; TBCT, total-body computed tomography; StoC, number of days between surgery and first administration of chemotherapy. *Statistically significant.

Table 2. Multivariable Cox regression analysis for risk of tumor metastasis in 70 dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy and adjuvant chemotherapy. Variables with a significance level of $P < 0.2$ at univariable analysis were included in the model.

Variable	Tumor metastasis	
	Hazard Ratio (95% CI)	P
Intact status	1.4 (0.8-2.4)	0.198
StoC >21 days	2.3 (1.3-4.0)	0.003*

Abbreviations: CI, confidence interval; StoC, number of days between surgery and first administration of chemotherapy. *Statistically significant.

Table 3. Multivariable Cox regression analysis for risk of death in 70 dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy and adjuvant chemotherapy. Variables with a significance level of $P < 0.2$ at univariable analysis were included in the model.

Variable	Death	
	Hazard Ratio (95% CI)	<i>P</i>
Intact status	1.6 (0.9-2.7)	0.098
StoC >21 days	2.5 (1.4-4.6)	0.002*
Staging without TBCT scan	1.4 (0.8-2.5)	0.303
No metronomic therapy	1.4 (0.8-2.3)	0.257

Abbreviations: CI, confidence interval; TBCT, total-body computed tomography; StoC, number of days between surgery and first administration of chemotherapy. *Statistically significant.

Table 4. Demographic information and distribution of variables potentially associated with prognosis of 70 dogs with non-metastatic splenic hemangiosarcoma undergoing splenectomy and adjuvant chemotherapy. Differences in data distribution were assessed with Chi-square test/Fisher's exact test (categorical variables) or Mann-Whitney U test (continuous variables).

Variable	StoC ≤21 days (<i>n</i> = 39)	StoC >21 days (<i>n</i> = 31)	<i>P</i>
Sex			0.477
<i>Male</i>	19	18	
<i>Female</i>	20	13	
Neutering status			0.029*
<i>Intact</i>	12	18	
<i>Neutered</i>	27	13	
Age (years)			0.258
<i>Median (range)</i>	9 (6 – 14)	10 (6 – 15)	
Weight (kg)			0.624
<i>Median (range)</i>	25.0 (8.9 – 48.6)	29.6 (5.6 – 58.0)	
Presence of symptoms			>0.999
<i>Yes</i>	35	28	
<i>No</i>	4	3	
Staging method			0.297
<i>TBCT</i>	14	7	

<i>Other</i>	25	24	
Hemoabdomen			>0.999
<i>Yes</i>	32	26	
<i>No</i>	7	5	
Anemia			>0.999
<i>Yes</i>	28	21	
<i>No</i>	9	6	
Thrombocytopenia			0.8
<i>Yes</i>	17	11	
<i>No</i>	20	16	
Coagulation disorders			>0.999
<i>Yes</i>	2	2	
<i>No</i>	26	21	
Blood products administration			0.726
<i>Yes</i>	5	3	
<i>No</i>	34	28	
Metronomic therapy			0.808
<i>Yes</i>	22	19	
<i>No</i>	17	12	
Grade III/IV toxic effects			0.496
<i>Yes</i>	4	5	
<i>No</i>	35	26	
Restaging time (days)			0.142
<i>Median (range)</i>	54 (16 – 78)	51 (18 – 111)	

Abbreviations: StOC, number of days between surgery and first administration of chemotherapy; TBCT, total-body computed tomography. *Statistically significant.